therapy that is optimal for disease control in patients with HR-LPCa. In this study, we compared the long-term oncological outcomes of RP and intensity-modulated radiation therapy (IMRT) for HR-LPCa at our institution using a propensity score-matched analysis.
INTRODUCTION AND OBJECTIVES:
We evaluated the efficacy and safety of prostate-directed radiotherapy with or without metastasis-directed radiotherapy in de novo oligometastatic patients who underwent combination of high-dose-rate prostate brachytherapy, external beam radiotherapy, and androgen deprivation therapy.
METHODS: Forty patients with bone metastasis and node positive prostate cancer were retrospectively analyzed. Of these, 22 (55%), 3 (7%), and 15 (38%) patients had N1M0, M1a, and M1b, respectively. Eighteen patients (45%) received metastasis-directed radiotherapy to all metastatic sites. All patients initially underwent ! 6 months of androgen deprivation therapy. Oligometastatic disease was defined as presence of five or fewer metastatic lesions. Median prostate-specific antigen (PSA) at diagnosis and follow-up period was 19.35 ng/ml and 62.5 months, respectively. RESULTS: Of the 40 patients, the 5-year castration-resistant prostate cancer (CRPC)-free survival rate and cancer-specific survival was 64.4% and 87.9%, respectively. Pre-treatment predictive value including PSA at diagnosis ! 20 ng/ml (HR 2.722; 95% CI: 1.003-7.392), positive biopsy core rate ! 51% (HR 4.677; 95% CI: 1.693-12.92), and Gleason grade group 5 (HR 2.993; 95% CI: 1.246-12.34) were significantly associated with worse outcomes for CRPC-free survival. Patients with metastasis-directed radiotherapy had significantly higher probability of achieving a PSA level of < 0.02 ng/ ml than those without the therapy (88.8% vs. 54.5%, p [ 0.0354) and consequently had a better CRPC-free survival than those without the therapy (HR 0.319; 95% CI: 0.116-0.877) (Figure 1 ). Prostatedirected radiotherapy with metastasis-directed radiotherapy did not significantly increase the incidences of genitourinary and gastrointestinal toxicities compared to prostate-directed radiotherapy alone.
CONCLUSIONS: This single-institutional study revealed the feasibility of combining prostate brachytherapy and metastasisdirected radiotherapy for de novo oligometastatic prostate cancer. This combined approach has potential to prolong CRPC-free survival.
Source of Funding: none

MP72-14 DISCORDANCE BETWEEN PATIENT-REPORTED INCONTINENCE AND PATIENT-REPORTED PAD USE FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY
Conner Brown*, Jared Winoker, Rollin Say, Richard Stock, Nelson Stone, New York, NY INTRODUCTION AND OBJECTIVES: We sought to characterize patients with self-reported incontinence and self-reported pad use following permanent prostate brachytherapy (PPB).
METHODS: We evaluated 2,277 men who underwent PPB AE EBRT for localized prostate cancer. Primary outcomes were patientreported incontinence (PRI) at last follow up visit, type of incontinence reported, and patient-reported pad use (PRP) at last follow up visit. The association of patient, disease, and treatment characteristics with PRI and PRP was assessed. Univariate analysis was performed using chi-squared, fisher's exact, student's t-test, and ANOVA. Multivariate analysis was performed using binomial and multinomial logistic regression.
RESULTS: Median follow up was 100 months. In total, 82 patients (3.6%) reported unresolved incontinence at last follow up, while only 17 reported using at least one pad. For patients reporting incontinence, 59 reported urge incontinence, 15 reported stress incontinence , and 8 reported mixed incontinence. Of the 17 patients using pads, 12 reported urge incontinence and 5 reported mixed incontinence, while none reported stress incontinence. In univariate analysis, the factors associated with increased PRI were post-treatment TURP (p[0. 
